Meta Biomed Co., Ltd. (KOSDAQ:059210)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,865.00
-10.00 (-0.26%)
At close: Sep 4, 2026

Meta Biomed Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
16,99310,98822,40210,0802,6289,522
Depreciation & Amortization
5,9425,4994,9814,2233,8603,571
Loss (Gain) From Sale of Assets
293.94-588.130.91-12.62-1,212-1,160
Asset Writedown & Restructuring Costs
707.61707.61-1,015487.37541.23
Loss (Gain) From Sale of Investments
-1,1177.68-349.53-90.29-53.65-51.16
Loss (Gain) on Equity Investments
-383.49-308.09-1,181-682.88-373.09-537.62
Provision & Write-off of Bad Debts
-273.53-204.72444.66-158.44-172.39-1,376
Other Operating Activities
3,4149,657-1,456-2,9262,115-1,637
Change in Accounts Receivable
-3,771-4,199597.84186.61-1,024-171.24
Change in Inventory
-3,308-4,532-2,514-470.44926.992,038
Change in Accounts Payable
-1,925145.12-807.66304.0593.14-1,503
Change in Other Net Operating Assets
1,1742,661513.17-1,2511,8841,900
Operating Cash Flow
17,74619,83322,63310,2179,15911,136
Operating Cash Flow Growth
-13.10%-12.37%121.52%11.55%-17.75%129.06%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-17,646-20,304-10,914-11,489-15,395-2,067
Sale of Property, Plant & Equipment
37.3888.7761.83128.067.451,413
Cash Acquisitions
-----2,295-2.45
Divestitures
8.328.32---535.01
Sale (Purchase) of Intangibles
-154.31-156.74-188.9-5.4385.95-33.29
Investment in Securities
8,46813,330-32,4211,116-167.96,349
Other Investing Activities
-39.75-35.4398.4-1,4513,186130
Investing Cash Flow
-8,826-6,569-43,363-11,701-14,5786,324

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-18,50060,70011,37537,0831,949
Long-Term Debt Repaid
--25,465-36,544-11,940-27,828-17,827
Net Debt Issued (Repaid)
-266.03-6,96524,156-565.379,255-15,878
Repurchase of Common Stock
-2,836--140.74--63.26-
Dividends Paid
-2,842-684.93-457.42-457.42-458.02-229.01
Other Financing Activities
-515.12-2,115-148-0-0
Financing Cash Flow
-6,458-9,76423,410-1,0238,734-16,107

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
571.89-60.761,04177.02-201.36121.38
Miscellaneous Cash Flow Adjustments
--00--00
Net Cash Flow
3,0333,4393,721-2,4303,1131,474

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
100.64-471.1711,719-1,271-6,2369,069
Free Cash Flow Growth
-99.00%----244.28%
Free Cash Flow Margin
0.10%-0.46%12.46%-1.53%-9.04%15.43%
Free Cash Flow Per Share
3.50-18.77432.22-55.59-272.48396.00
Levered Free Cash Flow
-8,524-14,4426,742-3,338-6,1755,650
Unlevered Free Cash Flow
-7,238-12,6639,081-1,891-5,3066,366

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
1,3041,5522,0942,1761,259733.31
Cash Income Tax Paid
1,033889.59163.5780379.03357.43
Change in Working Capital
-7,830-5,926-2,211-1,2311,8802,263